Paul A. Mahon - Mar 6, 2025 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Signature
/s/ John S. Hess, Jr. under Power of Attorney
Stock symbol
UTHR
Transactions as of
Mar 6, 2025
Transactions value $
-$945,689
Form type
4
Date filed
3/7/2025, 04:33 PM
Previous filing
Feb 21, 2025
Next filing
Apr 7, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $1.07M +6.55K +17.81% $163.30 43.3K Mar 6, 2025 Direct F1, F2
transaction UTHR Common Stock Disposed to Issuer -$2.02M -6.55K -15.12% $307.68 36.8K Mar 6, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Share Tracking Award Options Exercise $0 -6.55K -100% $0.00 0 Mar 6, 2025 Common Stock 6.55K $163.30 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.
F2 Includes 71 shares of common stock acquired on March 4, 2025 under the United Therapeutics Employee Stock Purchase Plan.
F3 Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.